Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences compared to last year

ProSense® breast cancer cryoablation procedures have been performed in major cities across the U.S.

CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), today reported a 70% increase in its U.S. active commercial install base of ProSense® for breast cancer cryoablation following U.S. Food and Drug Administration (FDA) marketing authorization in October 2025, reflecting accelerating commercial adoption, expanding physician demand and continued growth in the Company's U.S. footprint.

IceCure develops and commercializes its minimally invasive cryoablation technology that destroys tumors by freezing, offering an option to surgical tumor removal for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgery.

IceCure has continued to add new ProSense® systems to its installment base at clinics and hospitals across the U.S. As adoption expands, ProSense® breast cancer cryoablation procedures have been performed in major metropolitan areas throughout the country, including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, Memphis and many other communities.

The Company had strong engagement at two of the leading breast health conferences held this earlier year, the Society of Breast Imaging ("SBI") Annual Symposium and the American Society of Breast Surgeons ("ASBrS") Annual Meeting, where IceCure generated significantly more sales leads for ProSense® systems compared to the same events in 2025, prior to FDA authorization, reflecting significantly increased interest from physicians and healthcare providers.